{"title":"蘑菇对大脑的作用:蘑菇生物活性化合物的神经保护作用的综述。","authors":"Tamilselvan Amutha Gokul, Kamatchi Ramesh Kumar, Mani Rama Prabha, Veeramani Veeramanikandan, Bhathini Vaikuntavasan Pradeep, Fahad Al-Asmari, Fakhria A Al-Joufi, Mohamed Hussien, Tariq Aziz, Paulraj Balaji","doi":"10.1007/s11011-025-01716-5","DOIUrl":null,"url":null,"abstract":"<p><p>Neurodegenerative and neuropsychiatric diseases pose significant challenges to individuals' well-being and healthcare systems. These conditions share common mechanisms like oxidative stress, protein aggregation, inflammation, impaired neurotransmission, mitochondrial dysfunction, and excitotoxicity. Current treatments offer limited efficacy and often come with adverse effects. Mushrooms, recognized as a valuable cultural and nutritional resource, hold therapeutic potential. As a future superfood, they contribute to overall health and well-being. Various mushroom groups have been studied for their bioactive compounds, including polysaccharides, protein complexes, peptides, terpenoids, and phenolic compounds, demonstrating efficacy in different neurodegenerative conditions. Notably, edible mushrooms have shown promise in mitigating beta-amyloid-induced neurotoxicity. This review explores the utilization of mushroom biomolecules in treating neurodegenerative diseases, offering novel research insights with preclinical and clinical trials in both rat model and humans paving the way for the development and utilization of mushroom bioactive compounds as neuroprotective agents.</p>","PeriodicalId":18685,"journal":{"name":"Metabolic brain disease","volume":"40 7","pages":"283"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mushrooms for the brain: A review of the neuroprotective effects of mushroom bioactive compounds.\",\"authors\":\"Tamilselvan Amutha Gokul, Kamatchi Ramesh Kumar, Mani Rama Prabha, Veeramani Veeramanikandan, Bhathini Vaikuntavasan Pradeep, Fahad Al-Asmari, Fakhria A Al-Joufi, Mohamed Hussien, Tariq Aziz, Paulraj Balaji\",\"doi\":\"10.1007/s11011-025-01716-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Neurodegenerative and neuropsychiatric diseases pose significant challenges to individuals' well-being and healthcare systems. These conditions share common mechanisms like oxidative stress, protein aggregation, inflammation, impaired neurotransmission, mitochondrial dysfunction, and excitotoxicity. Current treatments offer limited efficacy and often come with adverse effects. Mushrooms, recognized as a valuable cultural and nutritional resource, hold therapeutic potential. As a future superfood, they contribute to overall health and well-being. Various mushroom groups have been studied for their bioactive compounds, including polysaccharides, protein complexes, peptides, terpenoids, and phenolic compounds, demonstrating efficacy in different neurodegenerative conditions. Notably, edible mushrooms have shown promise in mitigating beta-amyloid-induced neurotoxicity. This review explores the utilization of mushroom biomolecules in treating neurodegenerative diseases, offering novel research insights with preclinical and clinical trials in both rat model and humans paving the way for the development and utilization of mushroom bioactive compounds as neuroprotective agents.</p>\",\"PeriodicalId\":18685,\"journal\":{\"name\":\"Metabolic brain disease\",\"volume\":\"40 7\",\"pages\":\"283\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Metabolic brain disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11011-025-01716-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic brain disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11011-025-01716-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Mushrooms for the brain: A review of the neuroprotective effects of mushroom bioactive compounds.
Neurodegenerative and neuropsychiatric diseases pose significant challenges to individuals' well-being and healthcare systems. These conditions share common mechanisms like oxidative stress, protein aggregation, inflammation, impaired neurotransmission, mitochondrial dysfunction, and excitotoxicity. Current treatments offer limited efficacy and often come with adverse effects. Mushrooms, recognized as a valuable cultural and nutritional resource, hold therapeutic potential. As a future superfood, they contribute to overall health and well-being. Various mushroom groups have been studied for their bioactive compounds, including polysaccharides, protein complexes, peptides, terpenoids, and phenolic compounds, demonstrating efficacy in different neurodegenerative conditions. Notably, edible mushrooms have shown promise in mitigating beta-amyloid-induced neurotoxicity. This review explores the utilization of mushroom biomolecules in treating neurodegenerative diseases, offering novel research insights with preclinical and clinical trials in both rat model and humans paving the way for the development and utilization of mushroom bioactive compounds as neuroprotective agents.
期刊介绍:
Metabolic Brain Disease serves as a forum for the publication of outstanding basic and clinical papers on all metabolic brain disease, including both human and animal studies. The journal publishes papers on the fundamental pathogenesis of these disorders and on related experimental and clinical techniques and methodologies. Metabolic Brain Disease is directed to physicians, neuroscientists, internists, psychiatrists, neurologists, pathologists, and others involved in the research and treatment of a broad range of metabolic brain disorders.